BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update

Go back to BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update

Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 15c

May 10, 2016 9:28 AM EDT

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

... More